ad image

Phase 3 Trial

1 / 1
GBT
Clinical Trials

GBT Announces Efficacy Data from All Patients Enrolled in Phase 3 Study Sustained Improvements in Hemoglobin with Voxelotor

GBT

PR-M06-19-NI-025Jun 18, 2019
Eli Lilly and Company
Oncology

Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®

Eli Lilly and Company

PR-M01-19-NI-067Jan 23, 2019
BiondVax
PR-M10-18-NI-081

BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial

BiondVax

InvestmentOct 24, 2018
Takeda
Phase III Trial

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib

Takeda

PR-M07-18-NI-094Jul 27, 2018
Norgine
Phase III Trial

Endoscopy Publishes the Dayb Phase III Trial for Plenvu®(Ner1006), the First One Litre Peg Bowel Preparation[i]

Norgine

PR-M07-18-NI-089Jul 26, 2018
Array BioPharma
Clinical Data

Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In

Array BioPharma

PR-M06-18-NI-086Jun 26, 2018
Sage Therapeutics
Clinical Trials

Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting

Sage Therapeutics

PR-M06-18-NI-060Jun 18, 2018
Allergan, plc
Clinical Data

Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant

Allergan, plc

PR-M06-18-NI-051Jun 14, 2018
Northwest Biotherapeutics
Clinical Data

NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

Northwest Biotherapeutics

PR-M06-18-NI-009Jun 04, 2018
AbbVie
Trial Results

IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint

AbbVie

PR-M05-18-NI-102May 28, 2018
Pfizer
Phase 3 Trial

LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint

Pfizer

PR-M05-18-NI-077May 21, 2018
1 / 1